US20220331254A1 - Pellet and multi-unit pellet system (mups) - Google Patents
Pellet and multi-unit pellet system (mups) Download PDFInfo
- Publication number
- US20220331254A1 US20220331254A1 US17/856,817 US202217856817A US2022331254A1 US 20220331254 A1 US20220331254 A1 US 20220331254A1 US 202217856817 A US202217856817 A US 202217856817A US 2022331254 A1 US2022331254 A1 US 2022331254A1
- Authority
- US
- United States
- Prior art keywords
- weight
- pellets
- polymer
- pellet
- mups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008188 pellet Substances 0.000 title claims abstract description 151
- 229920000642 polymer Polymers 0.000 claims abstract description 77
- 239000011247 coating layer Substances 0.000 claims abstract description 35
- 239000004480 active ingredient Substances 0.000 claims abstract description 32
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims abstract description 27
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 24
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims abstract description 19
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011258 core-shell material Substances 0.000 claims abstract description 12
- 239000003826 tablet Substances 0.000 claims description 48
- 239000007891 compressed tablet Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 20
- 239000004014 plasticizer Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 239000011159 matrix material Substances 0.000 claims description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 13
- 229960003174 lansoprazole Drugs 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- -1 brighteners Substances 0.000 claims description 10
- 229960004770 esomeprazole Drugs 0.000 claims description 10
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 9
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 7
- 239000000612 proton pump inhibitor Substances 0.000 claims description 7
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 6
- 208000025865 Ulcer Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 229960002009 naproxen Drugs 0.000 claims description 6
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 6
- 231100000397 ulcer Toxicity 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims description 4
- 239000002876 beta blocker Substances 0.000 claims description 4
- 229940097320 beta blocking agent Drugs 0.000 claims description 4
- MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 claims description 4
- 229960003568 dexlansoprazole Drugs 0.000 claims description 4
- 239000004083 gastrointestinal agent Substances 0.000 claims description 4
- 229940127227 gastrointestinal drug Drugs 0.000 claims description 4
- 229960000381 omeprazole Drugs 0.000 claims description 4
- 229960005019 pantoprazole Drugs 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 4
- 229960004157 rabeprazole Drugs 0.000 claims description 4
- 206010019375 Helicobacter infections Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims description 3
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 3
- 210000001198 duodenum Anatomy 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 201000000052 gastrinoma Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003556 anti-epileptic effect Effects 0.000 claims description 2
- 230000002924 anti-infective effect Effects 0.000 claims description 2
- 230000003356 anti-rheumatic effect Effects 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003435 antirheumatic agent Substances 0.000 claims description 2
- 150000001556 benzimidazoles Chemical class 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002327 cardiovascular agent Substances 0.000 claims description 2
- 229940125692 cardiovascular agent Drugs 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 229940102838 methylmethacrylate Drugs 0.000 claims 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N 3-[3-[5-[5-(4,5-dihydroxy-6-methyloxan-2-yl)oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2h-furan-5-one Chemical compound C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000000813 peptide hormone Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 description 23
- 239000011248 coating agent Substances 0.000 description 22
- 238000007906 compression Methods 0.000 description 18
- 238000006386 neutralization reaction Methods 0.000 description 18
- 230000006835 compression Effects 0.000 description 17
- 229920003134 Eudragit® polymer Polymers 0.000 description 14
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 13
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 12
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 12
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 11
- 239000006185 dispersion Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000002417 nutraceutical Substances 0.000 description 9
- 235000021436 nutraceutical agent Nutrition 0.000 description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 230000004888 barrier function Effects 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 229920003165 Eudragit® NM 30 D Polymers 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000006069 physical mixture Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000004408 titanium dioxide Substances 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 3
- 229920003136 Eudragit® L polymer Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000008199 coating composition Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000007720 emulsion polymerization reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 3
- 230000008570 general process Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 101100065878 Caenorhabditis elegans sec-10 gene Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940082657 digitalis glycosides Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Definitions
- the invention is in the field of pellets and Multi-Unit Pellet Systems (MUPS), preferably compressed tablets, comprising a multitude of such pellets.
- MUPS Multi-Unit Pellet Systems
- WO2012/171575A1 describes a coating composition suitable for pharmaceutical applications.
- the coating composition comprises core-shell polymers derived from two-stage emulsion polymerization processes.
- EUDRAGIT® FL 30 D-55 (Evonik Nutrition & Care GmbH, Darmstadt, Germany) is a commercially available 30% by weight aqueous dispersion of a copolymer from a two-stage emulsion polymerization process, with a core of about 75% by weight, comprising polymerized units of 70% by weight of ethyl acrylate and 30% by weight of methyl methacrylate, and a shell of about 25% by weight, comprising polymerized units of 50% by weight ethyl acrylate and 50% by weight methacrylic acid.
- Multi-Unit Pellet System especially MUPS tablets
- the most frequent problem encountered is pellets film coat cracking and/or alteration of release profiles.
- Physical combination of anionic acrylates (example EUDRAGIT® L 30 D-55) with neutral acrylates (example EUDRAGIT® NM 30 D-55) has been described previously in order to take care of flexibility and release characteristics, but this approach suffers from multiple limitations like; 1. Need of additional cumbersome step of neutralization before mixing of two polymers. 2. Significant slowing down of release profiles after compression when high quantities of neutral acrylate polymer is used. 3. Cracking of films after compression, when low quantities of neutral acrylate polymer are used leading to loss of enteric protection.
- MUPS Multi-Unit Pellet System
- the invention is concerned with a pellet comprising a core, comprising one or more biologically active ingredients, and a coating layer onto the core, wherein the coating layer is comprising a mixture of a first polymer, which is a core-shell polymer, comprising 50 to 90, preferably 70 to 80% by weight of a core, comprising polymerized units of 60 to 80, preferably 65 to 75% by weight of ethyl acrylate and 20 to 40, preferably 25 to 35% by weight of methyl methacrylate, and 10 to 50, preferably 20 to 30% by weight of a shell, comprising polymerized units of 40 to 60, preferably 45 to 55% by weight of ethyl acrylate and 40 to 60, preferably 45 to 55% by weight of methacrylic acid, and a second polymer, comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate or methyl methacrylate, wherein the ratio of the first polymer to the second
- the invention discloses a pellet, comprising a coating, which can be used in the form of a multitude of pellets comprised in a Multi-Unit Pellet Systems (MUPS), preferably in a compressed tablet.
- MUPS Multi-Unit Pellet Systems
- Multi-Unit Pellet Systems is well known to a person skilled in the art of pharmacy, galenics or nutraceutical technology.
- a typical example for a Multi-Unit Pellet Systems (MUPS) is a compressed tablet comprising a multitude of pellets, comprising a core, comprising one or more biologically active ingredients, and a coating layer onto the core.
- the coated pellets are after compression bound in a matrix of pharmaceutically or nutraceutically excipients, such as microcrystalline cellulose or lactose. During the compression step of such tablets the pellets undergo high mechanical stress. Therefore, there is a need for flexible coatings that are on one hand resistant to the compression step and on the other hand provide certain active ingredient release profiles as required for the certain therapeutic purpose.
- the Invention Discloses
- a pellet comprising a core, comprising one or more biologically active ingredients, and a coating layer onto the core, wherein the coating layer is comprising a mixture of a first polymer, which is a core-shell polymer, comprising 50 to 90, preferably 70 to 80% by weight of a core, comprising polymerized units of 60 to 80, preferably 65 to 75% by weight of ethyl acrylate and 20 to 40, preferably 25 to 35% by weight of methyl methacrylate, and 10 to 50, preferably 20 to 30% by weight of a shell, comprising polymerized units of 40 to 60, preferably 45 to 55% by weight of ethyl acrylate and 40 to 60 preferabyl 45 to 55% by weight of methacrylic acid, and a second polymer, comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate or methyl methacrylate, wherein the ratio of the first polymer to the second polymer is from
- a preferred pellet is comprising a core, comprising one or more biologically active ingredients, and a coating layer onto the core, wherein the coating layer is comprising a mixture of a first polymer, which is a core-shell polymer, comprising 70 to 80% by weight of a core, comprising polymerized units of 65 to 75% by weight of ethyl acrylate and 25 to 35% by weight of methyl methacrylate, and 20 to 30% by weight of a shell, comprising polymerized units of 45 to 55% by weight of ethyl acrylate and 45 to 55% by weight of methacrylic acid, and a second polymer, comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate or methyl methacrylate, wherein the ratio of the first polymer to the second polymer is from 1:0.1 to 1:2.5, most preferred from 1:0.25 to 1:2.
- a first polymer which is a core-shell polymer, compris
- the core and/or the coating layer of the pellet may further comprise pharmaceutical or nutraceutical acceptable excipients.
- the pellet may comprise 40 to 90% by weight of the core and 10 to 60% by weight of the coating layer.
- the pellet comprises a core, comprising one or more biologically active ingredients.
- the core of the pellet may further comprise pharmaceutical or nutraceutical acceptable excipients or substrate pellets (nonpareilles, for instance sugar pellets).
- the core may comprise 1 to 100, preferably 10 to 50% by weight of the one or more biologically active ingredients and 0 to 99, preferably 50 to 90% by weight of pharmaceutical or nutraceutical acceptable excipients and/or substrate pellets (non pareilles)
- the core of the pellet may optionally comprise, as a part of the core, an additional separating layer as an outer layer, for instance a layer of a water-soluble polymer, such as hydroxypropyl methyl cellulose.
- the separating layer may have the function to separate the active ingredient in the core from the acidic groups of the coating layer and has essentially no influence on the active ingredient release.
- the amount of the separating layer may be from 5 to 60, preferably from 10 to 30% by weight related to the weight of the total core.
- the pellet comprises a coating layer onto the core, respectively on the separating layer of the core, wherein the coating layer is comprising a mixture of a first polymer and a second polymer, wherein the ratio of the first polymer to the second polymer is from about 1:0.1 to 1:10, preferably from 1:0.1 to 1:2.5, most preferred from 1: 0,25 to 1:2.
- the coating layer of the pellet may further comprise pharmaceutical or nutraceutical acceptable excipients, such as talc, TiO2, stearates or pigments.
- the coating layer comprises a first polymer which is a core-shell polymer, comprising 50 to 90, preferably 70 to 80% by weight of a core, comprising polymerized units of 60 to 80, preferably 65 to 75% by weight of ethyl acrylate and 20 to 40, preferably 25 to 35% by weight of methyl methacrylate, and 10 to 50, preferably 20 to 30% by weight of a shell, comprising polymerized units of 40 to 60, preferably 45 to 55% by weight of ethyl acrylate and 40 to 60, preferably 45 to 55% by weight of methacrylic acid.
- a first polymer which is a core-shell polymer, comprising 50 to 90, preferably 70 to 80% by weight of a core, comprising polymerized units of 60 to 80, preferably 65 to 75% by weight of ethyl acrylate and 20 to 40, preferably 25 to 35% by weight of methyl methacrylate, and 10 to 50, preferably 20 to 30% by weight of a shell,
- a suitable first polymer is EUDRAGIT® FL 30 D-55 (Evonik Nutrition & Care GmbH, Darmstadt, Germany), which is a commercially available 30% by weight aqueous dispersion of a copolymer from a two-stage emulsion polymerization process, with a core of about 75% by weight, comprising polymerized units of 70% by weight of ethyl acrylate and 30% by weight of methyl methacrylate, and a shell of about 25% by weight, comprising polymerized units of 50% by weight ethyl acrylate and 50% by weight methacrylic acid.
- the coating layer comprises a second polymer, comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate or methyl methacrylate.
- the second polymer is not a core-shell polymer.
- the coating layer may comprise a second polymer comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of methyl methacrylate (type EUDRAGIT® L).
- the coating layer comprises a second polymer comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate (type EUDRAGIT® L 100-55).
- a second polymer comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate (type EUDRAGIT® L 100-55).
- a suitable second polymer is EUDRAGIT® L 100-55 Evonik Nutrition & Care GmbH, Darmstadt, Germany), which is a copolymer comprising polymerized units of 50% by weight of methacrylic acid and 50% by weight of ethyl acrylate.
- EUDRAGIT® L 30 D-55 is a 30% by weight aqueous dispersion of EUDRAGIT® L 100-55.
- a preferred ratio of the amount of polymer by weight in the core of the first polymer to the amount of polymer in the shell of the first polymer and the second polymer may be in the range of 5:95 to 70:30, preferably in the range of 20:80 to 60:40 (in the examples referred to as “Ratio of NM:L in coating”).
- the combination of the first and the second polymer in the coating layer of the pellet does not need any essential addition or no addition at all of a plasticizer. This facilitates the composition, the processing and reduces the risk of incompatibilities or undesired side-effects, that may be potentially caused in some cases by the addition of plasticizers.
- the coating layer may comprise no essential amounts, 2% by weight or less (0 to 2% by weight) of a plasticizer or does not comprise a plasticizer at all.
- Plasticizers may be defined in that they achieve through physical interaction with a polymer a reduction in the glass transition temperature and promote film formation, depending on the added amount. Suitable substances usually have a molecular weight of between 100 and 20,000 and comprise one or more hydrophilic groups in the molecule, e.g. hydroxyl, ester or amino groups.
- the coating layer may comprise no essential amounts of a plasticizer, preferably 2% by weight or less (0 to 2% by weight) of a plasticizer, which is selected from the groups of alkyl citrates, glycerol esters, alkyl phthalates, alkyl sebacates, sucrose esters, sorbitan esters and polyethylene glycols.
- a plasticizer which is selected from the groups of alkyl citrates, glycerol esters, alkyl phthalates, alkyl sebacates, sucrose esters, sorbitan esters and polyethylene glycols.
- the coating layer may preferably comprise no plasticizer at all.
- the coating layer may comprise no essential amounts of a plasticizer, preferably 2% by weight or less (0 to 2% by weight) of a plasticizer, which is selected from triethyl citrate (TEC), acetyl triethyl citrate (ATEC), diethyl sebacate and dibutyl sebacate (DBS), glycerol, propylene glycol, polyethylene glycols 200 to 12,000 and castor oil.
- TEC triethyl citrate
- ATC acetyl triethyl citrate
- DBS dibutyl sebacate
- glycerol glycerol
- propylene glycol polyethylene glycols 200 to 12,000 and castor oil.
- the coating layer may preferably comprise no plasticizer at all.
- the pellet comprises one or more biologically active ingredients that may be selected from active pharmaceutical ingredients and active nutraceutical ingredients.
- the one or more biologically active ingredient may be selected from the groups of analgetics, antibiotics or anti-infectives, antibodies, antiepileptics, antigens from plants, antirheumatics, betablocker, benzimidazole derivatives, beta-blocker, cardiovascular drugs, chemotherapeutics, CNS drugs, digitalis glycosides, gastrointestinal drugs, e.g. proton pump inhibitors, combinations of proton pump inhibitors with a nonsteroidal anti-inflammatory drug (NSAID), enzymes, hormons, liquid or solid natural extracts, oligonucleotides, peptidhormon proteins, therapeutical bacteria, peptides, proteins, urology drugs and vaccines, including salt-forms, such as aspartates or hydrochlorides.
- NSAID nonsteroidal anti-inflammatory drug
- the one or more biologically active ingredients may be selected from gastrointestinal drugs, preferably from proton pump inhibitors, most preferably from esomeprazole, dexlansoprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole or any combinations thereof, and a combination of esomeprazole and naproxen.
- the one or more biologically active ingredients may be selected from a combination of a proton pump inhibitor and a further active pharmaceutical ingredient.
- a combination may be esomeprazole and naproxen (known from VimovoTM, AstraZeneca AB, Sweden).
- MUPS Multi-Unit Pellet System
- MUPS Multi-Unit Pellet Systems
- pellets shall be understood in that for instance about 10 to 100,000, preferably about 20 to 10,000, more preferably 50 to 2,000 pellets may be comprised per single dosage unit of the Multi-Unit Pellet System (MUPS), which may be a single capsule, a single sachet or a single tablet.
- MUPS Multi-Unit Pellet System
- the Multi-Unit Pellet System is comprising a multitude of the pellets as disclosed.
- the Multi-Unit Pellet System wherein the multitude of pellets is comprised may be a capsule, in a sachet or in a tablet.
- the average particle size d50 of the pellets may be in the range of 1 to 2000, preferably in the range of 10 to 1000, most preferably in the range of 100 to 600 ⁇ m.
- the average diameter may be determined by sieving or by laser diffraction according to the United States Pharmacopeia 36 (USP) chapter ⁇ 429>and European Pharmacopeia 7.0 (EP) chapter 2.9.31.
- USP United States Pharmacopeia 36
- EP European Pharmacopeia 7.0
- the light scattered by the particles at various angles is measured by a multi-element detector, and numerical values relating to the scattering pattern are then recorded for subsequent analysis.
- the numerical scattering values are then transformed, using an appropriate optical model and mathematical procedure, to yield the proportion of total volume to a discrete number of size classes forming a volumetric particle size distribution (d50 describes a particle diameter corresponding to 50% of cumulative undersize distribution).
- the Multi-Unit Pellet System is a capsule, preferably a hard-shell capsule, the capsule is comprising a multitude of pellets.
- Such a capsule dosage form may be of specific advantage since it is not necessary to add effective amounts of plasticizers to the pellet coating. This facilitates the composition, the processing and reduces the risk of incompatibilities or unwanted side effects, that may be caused by the addition of plasticizers.
- a sachet may have the form of a sealed packet containing a multitude of pellets embedded in pharmaceutical or nutraceutical excipients.
- the sachet is comprising a multitude of pellets.
- Such a sachet dosage form may be of specific advantage since it is not necessary to add effective amounts of plasticizers to the pellet coating. This facilitates the composition, the processing and reduces the risk of incompatibilities or undesired side effects, that may be potentially caused in some cases by the addition of plasticizers.
- the tablet may be a compressed tablet, comprising the multitude of pellets embedded in matrix excipients.
- the compressed tablet may comprise 30 to 80, preferably 40 to 70% by weight of matrix excipients and 70 to 20, preferably 60 to 30% by weight pellets.
- Matrix excipients may be selected from the group of antioxidants, brighteners, binding agents, cushioning agents, flavoring agents, flow aids, glidants, penetration-promoting agents, pigments, plasticizers, polymers, pore-forming agents and stabilizers or any combinations thereof.
- the matrix excipients may comprise microcrystalline cellulose, glycerol monostearate, lactose, silica, croscarmellose sodium and/or sodium stearyl fumarate.
- the compressed tablet may comprise 20 to 60% by weight of pellets and 40 to 80% by weight of matrix excipients.
- the weight of the compressed tablet may be from 50 to 2000 mg, preferably 100 to 1000 mg and most preferably from 200 to 800 mg.
- the forces applied in the compression process may be in the range of 1 bis 10 kN, preferably 2 - 6 kN.
- the resulting tablet hardness may be in the range of 50 to 250, preferably 80 to 150 N. Methods and equipment for determining the hardness of a tablet are well known to a skilled person in the field of pharmacy, galenics or nutraceutical technology.
- the compressed tablet as disclosed may be characterized in that the release of the biologically active ingredient from the compressed tablets (including the pellets in their matrix) is higher than that of the pellets. Usually such a release profile is acceptable and no calculation of a similarity factor F2 is necessary.
- the compressed tablet as disclosed may be further characterized in that the release curves of the biologically active ingredient from the compressed tablets (including the pellets in their matrix) is faster in a pH 4.5 medium or higher in a pH 6.8 medium (according to USP) than that of the pellets.
- a release profile is acceptable and no calculation of a similarity factor F2 is necessary.
- the compressed tablet as disclosed may also be characterized in that the release curves, respectively the dissolution profiles of the biologically active ingredient from the pellets and that of the compressed tablets (including the pellets in their matrix) show a similarity factor, F2-value, of 50 or more. Two dissolution profiles are considered similar when the f2 value is ⁇ 50. Thus, these release profiles are also acceptable.
- the F2-value is known to the skilled person from the requirements for bioequivalence studies as defined by Food and Drug Administration (FDA) of the United States of America. These are for example available in the documents like “Guidance for Industry; Waiver if In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on Biopharmaceutics Classification System (U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August 2000) or other from versions of this document, or from other document or guidelines from the FDA or CDER concerning bioavailability and bioequivalence Studies. All these documents are available in the Internet and well known to the skilled person in the field of pharmacy and galenics. In the above-mentioned document from August 2000 the calculation of the similarity factor (f2) is defined on p. 7:
- the similarity factor is a logarithmic reciprocal square root transformation of the sum of squared error and is a measurement of the similarity in the percent (%) of dissolution between the two curves.
- the release rates of the one or more biologically active ingredient(s) from the pellets and that of the compressed tablets should be preferably 10% or less after 1 hour in 0.1 HCl and more than 50% in subsequent pH 6.8 buffer (phosphate-buffer according to USP (e.g. USP-42-NF-37, March 2019) after 2 hours at pH 6.8.
- pH 6.8 buffer phosphate-buffer according to USP (e.g. USP-42-NF-37, March 2019) after 2 hours at pH 6.8.
- USP-42-NF-37 e.g. USP-42-NF-37, March 2019
- the determination of the release rates according to USP is well known to a skilled person (USP-42-NF-37, March 2019, Apparatus USP type II (Paddle), 75 RPM).
- MUPS Multi-Unit Pellet System
- a core-shell polymer comprising 50 to 90, preferably 70 to 80% by weight of a core, comprising polymerized units of 60 to 80, preferably 65 to 75% by weight of ethyl acrylate and 20 to 40, preferably 25 to 35% by weight of methyl methacrylate, and 10 to 50, preferably 20 to 30% by weight of a shell, comprising polymerized units of 40 to 60, preferably 45 to 55% by weight of ethyl acrylate and 40 to 60, preferably 45 to 55 by weight of methacrylic acid, and a second polymer, polymerized from 40 to 60% by weight of methacrylic acid and 40 to 60% by weight of ethyl acrylate or methyl methacrylate, wherein
- a Multi-Unit Pellet System comprising a biologically active ingredient, preferably a compressed tablet, for use as a medicament in the therapy and treatment of a disease of the human or animal body, wherein the disease is selected from ulcers of the stomach and duodenum, NSAID-induced ulcers, Helicobacter pylori infections, gastrointestinal reflux disease or Zollinger-Ellison syndrome, arthrosis, pain and inflammation and wherein the biologically active ingredient is selected from esomeprazole, dexlansoprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole or any combinations thereof and from a combination of esomeprazole and naproxen.
- a biologically active ingredient preferably a compressed tablet
- a Multi-Unit Pellet System comprising a biologically active ingredient, preferably a compressed tablet, for use (method of treatment) as a medicament in the therapy and treatment of a disease of the human or animal body, wherein the disease is selected from ulcers of the stomach and duodenum, NSAID-induced ulcers, Helicobacter pylori infections, gastrointestinal reflux disease or Zollinger-Ellison syndrome, arthrosis, pain and inflammation and wherein the biologically active ingredient is selected from a combination of a proton pump inhibitor with a nonsteroidal anti-inflammatory drug (NSAID), preferably a combination of esomeprazole and naproxen.
- NSAID nonsteroidal anti-inflammatory drug
- Pellets further EUDRAGIT ® FL 30 D-55 compressed into tablets along with excipients Formulation details Pellets Tablets Pellets Tablets Pellets Tablets Pellets Tablets Ratio of NM:L in coating 75:25 — 75:25 — 50:50 — 50:50 — Process without additional Yes — Yes — No — No — neutralization step
- Polymeric coat build up (% 10 — 30 — 20 — 30 — — w/w) w.r.t core Enteric protection ( ⁇ 10% Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes release in 0.1N HCl, 1 hr) % Drug release within 2 hrs No No No No Yes Yes Yes Yes of pH 6.8 buffer exposure more than 50% Drug release in 1 hr** 0.44** 3.10** 1.30** 3.32** 0.00** 2.97** 3.78** 2.98** 0.1N HCl 0.5 hr 30.00 27.18 21.83 10.35 84.29 66.85 46.98 46.17 followed by pH 1 h
- Pellets further Examples compressed into tablets along with excipients Formulation details Pellets Tablets Pellets Tablets Ratio of NM:L in coating 30:70 — 30:70 — Process without additional neutralization No — No — step Polymeric coat build up (% w/w) w.r.t 20 — 30 — core Enteric protection ( ⁇ 10% release in 0.1N Yes No Yes Yes HCl, 1 hr) % Drug release within 2 hrs of pH 6.8 Yes Yes Yes Yes buffer exposure more than 50% Drug release 1 hr** 0.05** 9.74** 0.35** 8.73** in 0.1 N HCl 0.5 hr 77.32 54.10 26.68 26.34 followed by 1 hr 100.00 70.80 92.93 61.65 pH 6.8 1.5 hr 103.00 77.74 99.99 70.81 2 hr — — — F2 value* comparing dissolution profiles 32 33 of pellets and compressed tablets ( ⁇ 50% denotes similarity) Comments Not acceptable.
- Pellets and tablet dissolution Not acceptable. Pellets and tablet profiles significantly dissimilar, dissolution profiles significantly Additional neutralization step needed. dissimilar. Additional neutralization step needed. *No F2 verification needed if the release in tablets is faster than pellets in buffer phase; **Release in 0.1 N HCl.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
A pellet contains a core, which contains one or more biologically active ingredients, and a coating layer on the core. The coating layer contains a mixture of a first polymer and a second polymer. The first polymer is a core-shell polymer, containing 50 to 90% by weight of a core, containing polymerized units of 60 to 80% by weight of ethyl acrylate and 20 to 40% by weight of methyl methacrylate; and 10 to 50% by weight of a shell, containing polymerized units of 40 to 60% by weight of ethyl acrylate and 40 to 60% by weight of methacrylic acid. The second polymer contains polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate or methyl methacrylate. A Multi-Unit Pellet System (MUPS) contains a multitude of the pellets.
Description
- The invention is in the field of pellets and Multi-Unit Pellet Systems (MUPS), preferably compressed tablets, comprising a multitude of such pellets.
- WO2012/171575A1 describes a coating composition suitable for pharmaceutical applications. The coating composition comprises core-shell polymers derived from two-stage emulsion polymerization processes.
- EUDRAGIT® FL 30 D-55 (Evonik Nutrition & Care GmbH, Darmstadt, Germany) is a commercially available 30% by weight aqueous dispersion of a copolymer from a two-stage emulsion polymerization process, with a core of about 75% by weight, comprising polymerized units of 70% by weight of ethyl acrylate and 30% by weight of methyl methacrylate, and a shell of about 25% by weight, comprising polymerized units of 50% by weight ethyl acrylate and 50% by weight methacrylic acid.
- When formulating Multi-Unit Pellet System (MUPS), especially MUPS tablets, the most frequent problem encountered is pellets film coat cracking and/or alteration of release profiles. Physical combination of anionic acrylates (example EUDRAGIT® L 30 D-55) with neutral acrylates (example EUDRAGIT® NM 30 D-55) has been described previously in order to take care of flexibility and release characteristics, but this approach suffers from multiple limitations like; 1. Need of additional cumbersome step of neutralization before mixing of two polymers. 2. Significant slowing down of release profiles after compression when high quantities of neutral acrylate polymer is used. 3. Cracking of films after compression, when low quantities of neutral acrylate polymer are used leading to loss of enteric protection. Thus, there is a need to improve the coating composition and process for enteric coating of Multi-Unit Pellet System (MUPS) dosage forms intended to be compressed into tablets.
- The invention is concerned with a pellet comprising a core, comprising one or more biologically active ingredients, and a coating layer onto the core, wherein the coating layer is comprising a mixture of a first polymer, which is a core-shell polymer, comprising 50 to 90, preferably 70 to 80% by weight of a core, comprising polymerized units of 60 to 80, preferably 65 to 75% by weight of ethyl acrylate and 20 to 40, preferably 25 to 35% by weight of methyl methacrylate, and 10 to 50, preferably 20 to 30% by weight of a shell, comprising polymerized units of 40 to 60, preferably 45 to 55% by weight of ethyl acrylate and 40 to 60, preferably 45 to 55% by weight of methacrylic acid, and a second polymer, comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate or methyl methacrylate, wherein the ratio of the first polymer to the second polymer is from about 1:0.1 to 1:10, preferably from 1:0.1 to 1:2.5, most preferred from 1:0.25 to 1:2. Also disclosed is a Multi-Unit Pellet System (MUPS), preferably a compressed tablet, comprising a multitude of the pellets.
- The invention discloses a pellet, comprising a coating, which can be used in the form of a multitude of pellets comprised in a Multi-Unit Pellet Systems (MUPS), preferably in a compressed tablet.
- The term Multi-Unit Pellet Systems (MUPS) is well known to a person skilled in the art of pharmacy, galenics or nutraceutical technology. A typical example for a Multi-Unit Pellet Systems (MUPS) is a compressed tablet comprising a multitude of pellets, comprising a core, comprising one or more biologically active ingredients, and a coating layer onto the core. The coated pellets are after compression bound in a matrix of pharmaceutically or nutraceutically excipients, such as microcrystalline cellulose or lactose. During the compression step of such tablets the pellets undergo high mechanical stress. Therefore, there is a need for flexible coatings that are on one hand resistant to the compression step and on the other hand provide certain active ingredient release profiles as required for the certain therapeutic purpose.
- a pellet comprising a core, comprising one or more biologically active ingredients, and a coating layer onto the core, wherein the coating layer is comprising a mixture of a first polymer, which is a core-shell polymer, comprising 50 to 90, preferably 70 to 80% by weight of a core, comprising polymerized units of 60 to 80, preferably 65 to 75% by weight of ethyl acrylate and 20 to 40, preferably 25 to 35% by weight of methyl methacrylate, and 10 to 50, preferably 20 to 30% by weight of a shell, comprising polymerized units of 40 to 60, preferably 45 to 55% by weight of ethyl acrylate and 40 to 60 preferabyl 45 to 55% by weight of methacrylic acid, and a second polymer, comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate or methyl methacrylate, wherein the ratio of the first polymer to the second polymer is from about 1:0.1 to 1:10, preferably from 1:0.1 to 1:2.5, most preferred from 1:0.25 to 1:2.
- A preferred pellet is comprising a core, comprising one or more biologically active ingredients, and a coating layer onto the core, wherein the coating layer is comprising a mixture of a first polymer, which is a core-shell polymer, comprising 70 to 80% by weight of a core, comprising polymerized units of 65 to 75% by weight of ethyl acrylate and 25 to 35% by weight of methyl methacrylate, and 20 to 30% by weight of a shell, comprising polymerized units of 45 to 55% by weight of ethyl acrylate and 45 to 55% by weight of methacrylic acid, and a second polymer, comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate or methyl methacrylate, wherein the ratio of the first polymer to the second polymer is from 1:0.1 to 1:2.5, most preferred from 1:0.25 to 1:2.
- The core and/or the coating layer of the pellet may further comprise pharmaceutical or nutraceutical acceptable excipients.
- The pellet may comprise 40 to 90% by weight of the core and 10 to 60% by weight of the coating layer.
- The pellet comprises a core, comprising one or more biologically active ingredients.
- The core of the pellet may further comprise pharmaceutical or nutraceutical acceptable excipients or substrate pellets (nonpareilles, for instance sugar pellets).
- The core may comprise 1 to 100, preferably 10 to 50% by weight of the one or more biologically active ingredients and 0 to 99, preferably 50 to 90% by weight of pharmaceutical or nutraceutical acceptable excipients and/or substrate pellets (non pareilles)
- The core of the pellet may optionally comprise, as a part of the core, an additional separating layer as an outer layer, for instance a layer of a water-soluble polymer, such as hydroxypropyl methyl cellulose. The separating layer may have the function to separate the active ingredient in the core from the acidic groups of the coating layer and has essentially no influence on the active ingredient release. The amount of the separating layer may be from 5 to 60, preferably from 10 to 30% by weight related to the weight of the total core.
- The pellet comprises a coating layer onto the core, respectively on the separating layer of the core, wherein the coating layer is comprising a mixture of a first polymer and a second polymer, wherein the ratio of the first polymer to the second polymer is from about 1:0.1 to 1:10, preferably from 1:0.1 to 1:2.5, most preferred from 1: 0,25 to 1:2.
- The coating layer of the pellet may further comprise pharmaceutical or nutraceutical acceptable excipients, such as talc, TiO2, stearates or pigments.
- The coating layer comprises a first polymer which is a core-shell polymer, comprising 50 to 90, preferably 70 to 80% by weight of a core, comprising polymerized units of 60 to 80, preferably 65 to 75% by weight of ethyl acrylate and 20 to 40, preferably 25 to 35% by weight of methyl methacrylate, and 10 to 50, preferably 20 to 30% by weight of a shell, comprising polymerized units of 40 to 60, preferably 45 to 55% by weight of ethyl acrylate and 40 to 60, preferably 45 to 55% by weight of methacrylic acid.
- A suitable first polymer is EUDRAGIT® FL 30 D-55 (Evonik Nutrition & Care GmbH, Darmstadt, Germany), which is a commercially available 30% by weight aqueous dispersion of a copolymer from a two-stage emulsion polymerization process, with a core of about 75% by weight, comprising polymerized units of 70% by weight of ethyl acrylate and 30% by weight of methyl methacrylate, and a shell of about 25% by weight, comprising polymerized units of 50% by weight ethyl acrylate and 50% by weight methacrylic acid.
- The coating layer comprises a second polymer, comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate or methyl methacrylate. The second polymer is not a core-shell polymer.
- The coating layer may comprise a second polymer comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of methyl methacrylate (type EUDRAGIT® L).
- Preferably the coating layer comprises a second polymer comprising polymerized units of 40 to 60% by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate (type EUDRAGIT® L 100-55).
- A suitable second polymer is EUDRAGIT® L 100-55 Evonik Nutrition & Care GmbH, Darmstadt, Germany), which is a copolymer comprising polymerized units of 50% by weight of methacrylic acid and 50% by weight of ethyl acrylate. EUDRAGIT® L 30 D-55 is a 30% by weight aqueous dispersion of EUDRAGIT® L 100-55.
- Ratio of the amount of polymer in the core of the first polymer to the amount of polymer in the shell of the first polymer and the second polymer
- A preferred ratio of the amount of polymer by weight in the core of the first polymer to the amount of polymer in the shell of the first polymer and the second polymer may be in the range of 5:95 to 70:30, preferably in the range of 20:80 to 60:40 (in the examples referred to as “Ratio of NM:L in coating”).
- It is an advantage that the combination of the first and the second polymer in the coating layer of the pellet does not need any essential addition or no addition at all of a plasticizer. This facilitates the composition, the processing and reduces the risk of incompatibilities or undesired side-effects, that may be potentially caused in some cases by the addition of plasticizers.
- The coating layer may comprise no essential amounts, 2% by weight or less (0 to 2% by weight) of a plasticizer or does not comprise a plasticizer at all.
- Plasticizers may be defined in that they achieve through physical interaction with a polymer a reduction in the glass transition temperature and promote film formation, depending on the added amount. Suitable substances usually have a molecular weight of between 100 and 20,000 and comprise one or more hydrophilic groups in the molecule, e.g. hydroxyl, ester or amino groups.
- The coating layer may comprise no essential amounts of a plasticizer, preferably 2% by weight or less (0 to 2% by weight) of a plasticizer, which is selected from the groups of alkyl citrates, glycerol esters, alkyl phthalates, alkyl sebacates, sucrose esters, sorbitan esters and polyethylene glycols.
- The coating layer may preferably comprise no plasticizer at all.
- The coating layer may comprise no essential amounts of a plasticizer, preferably 2% by weight or less (0 to 2% by weight) of a plasticizer, which is selected from triethyl citrate (TEC), acetyl triethyl citrate (ATEC), diethyl sebacate and dibutyl sebacate (DBS), glycerol, propylene glycol, polyethylene glycols 200 to 12,000 and castor oil. The coating layer may preferably comprise no plasticizer at all.
- The pellet comprises one or more biologically active ingredients that may be selected from active pharmaceutical ingredients and active nutraceutical ingredients.
- The one or more biologically active ingredient may be selected from the groups of analgetics, antibiotics or anti-infectives, antibodies, antiepileptics, antigens from plants, antirheumatics, betablocker, benzimidazole derivatives, beta-blocker, cardiovascular drugs, chemotherapeutics, CNS drugs, digitalis glycosides, gastrointestinal drugs, e.g. proton pump inhibitors, combinations of proton pump inhibitors with a nonsteroidal anti-inflammatory drug (NSAID), enzymes, hormons, liquid or solid natural extracts, oligonucleotides, peptidhormon proteins, therapeutical bacteria, peptides, proteins, urology drugs and vaccines, including salt-forms, such as aspartates or hydrochlorides.
- Preferably, the one or more biologically active ingredients may be selected from gastrointestinal drugs, preferably from proton pump inhibitors, most preferably from esomeprazole, dexlansoprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole or any combinations thereof, and a combination of esomeprazole and naproxen.
- Preferably, the one or more biologically active ingredients may be selected from a combination of a proton pump inhibitor and a further active pharmaceutical ingredient. An example for such a combination may be esomeprazole and naproxen (known from Vimovo™, AstraZeneca AB, Sweden).
- The term Multi-Unit Pellet Systems (MUPS) is well known to a person skilled in the art of pharmacy, galenics or nutraceutical technology.
- The term “a multitude of pellets” shall be understood in that for instance about 10 to 100,000, preferably about 20 to 10,000, more preferably 50 to 2,000 pellets may be comprised per single dosage unit of the Multi-Unit Pellet System (MUPS), which may be a single capsule, a single sachet or a single tablet.
- The Multi-Unit Pellet System (MUPS) is comprising a multitude of the pellets as disclosed.
- The Multi-Unit Pellet System (MUPS), wherein the multitude of pellets is comprised may be a capsule, in a sachet or in a tablet.
- The average particle size d50 of the pellets may be in the range of 1 to 2000, preferably in the range of 10 to 1000, most preferably in the range of 100 to 600 μm. The average diameter may be determined by sieving or by laser diffraction according to the United States Pharmacopeia 36 (USP) chapter <429>and European Pharmacopeia 7.0 (EP) chapter 2.9.31. The laser diffraction method is based on the phenomenon that particles scatter light in all directions with an intensity pattern that is dependent on particle size. A representative sample, dispersed at an adequate concentration in a suitable liquid or gas, is passed through the beam of a monochromic light source usually from a laser. The light scattered by the particles at various angles is measured by a multi-element detector, and numerical values relating to the scattering pattern are then recorded for subsequent analysis. The numerical scattering values are then transformed, using an appropriate optical model and mathematical procedure, to yield the proportion of total volume to a discrete number of size classes forming a volumetric particle size distribution (d50 describes a particle diameter corresponding to 50% of cumulative undersize distribution).
- When the Multi-Unit Pellet System (MUPS) is a capsule, preferably a hard-shell capsule, the capsule is comprising a multitude of pellets.
- Such a capsule dosage form may be of specific advantage since it is not necessary to add effective amounts of plasticizers to the pellet coating. This facilitates the composition, the processing and reduces the risk of incompatibilities or unwanted side effects, that may be caused by the addition of plasticizers.
- A sachet may have the form of a sealed packet containing a multitude of pellets embedded in pharmaceutical or nutraceutical excipients.
- When the Multi-Unit Pellet System (MUPS) is a sachet, the sachet is comprising a multitude of pellets.
- Such a sachet dosage form may be of specific advantage since it is not necessary to add effective amounts of plasticizers to the pellet coating. This facilitates the composition, the processing and reduces the risk of incompatibilities or undesired side effects, that may be potentially caused in some cases by the addition of plasticizers.
- When the Multi-Unit Pellet System (MUPS) is a tablet, the tablet may be a compressed tablet, comprising the multitude of pellets embedded in matrix excipients.
- The compressed tablet may comprise 30 to 80, preferably 40 to 70% by weight of matrix excipients and 70 to 20, preferably 60 to 30% by weight pellets.
- Matrix excipients may be selected from the group of antioxidants, brighteners, binding agents, cushioning agents, flavoring agents, flow aids, glidants, penetration-promoting agents, pigments, plasticizers, polymers, pore-forming agents and stabilizers or any combinations thereof.
- Preferably the matrix excipients may comprise microcrystalline cellulose, glycerol monostearate, lactose, silica, croscarmellose sodium and/or sodium stearyl fumarate.
- The compressed tablet may comprise 20 to 60% by weight of pellets and 40 to 80% by weight of matrix excipients.
- The weight of the compressed tablet may be from 50 to 2000 mg, preferably 100 to 1000 mg and most preferably from 200 to 800 mg.
- The forces applied in the compression process may be in the range of 1 bis 10 kN, preferably 2 - 6 kN. The resulting tablet hardness may be in the range of 50 to 250, preferably 80 to 150 N. Methods and equipment for determining the hardness of a tablet are well known to a skilled person in the field of pharmacy, galenics or nutraceutical technology.
- The compressed tablet as disclosed may be characterized in that the release of the biologically active ingredient from the compressed tablets (including the pellets in their matrix) is higher than that of the pellets. Usually such a release profile is acceptable and no calculation of a similarity factor F2 is necessary.
- The compressed tablet as disclosed may be further characterized in that the release curves of the biologically active ingredient from the compressed tablets (including the pellets in their matrix) is faster in a pH 4.5 medium or higher in a pH 6.8 medium (according to USP) than that of the pellets. Usually such a release profile is acceptable and no calculation of a similarity factor F2 is necessary.
- The compressed tablet as disclosed may also be characterized in that the release curves, respectively the dissolution profiles of the biologically active ingredient from the pellets and that of the compressed tablets (including the pellets in their matrix) show a similarity factor, F2-value, of 50 or more. Two dissolution profiles are considered similar when the f2 value is ≥50. Thus, these release profiles are also acceptable.
- F2-value
- The F2-value is known to the skilled person from the requirements for bioequivalence studies as defined by Food and Drug Administration (FDA) of the United States of America. These are for example available in the documents like “Guidance for Industry; Waiver if In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on Biopharmaceutics Classification System (U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August 2000) or other from versions of this document, or from other document or guidelines from the FDA or CDER concerning bioavailability and bioequivalence Studies. All these documents are available in the Internet and well known to the skilled person in the field of pharmacy and galenics. In the above-mentioned document from August 2000 the calculation of the similarity factor (f2) is defined on p. 7:
- When comparing the test and reference products, dissolution profiles should be compared using a similarity factor (f2). The similarity factor is a logarithmic reciprocal square root transformation of the sum of squared error and is a measurement of the similarity in the percent (%) of dissolution between the two curves.
-
f2=50·log {[1+(1/n)Σt=1n (Rt−Tt)2]−0.5·100} - Two dissolution profiles are considered similar when the f2 value is ≥50.
- The release rates of the one or more biologically active ingredient(s) from the pellets and that of the compressed tablets should be preferably 10% or less after 1 hour in 0.1 HCl and more than 50% in subsequent pH 6.8 buffer (phosphate-buffer according to USP (e.g. USP-42-NF-37, March 2019) after 2 hours at pH 6.8. The determination of the release rates according to USP is well known to a skilled person (USP-42-NF-37, March 2019, Apparatus USP type II (Paddle), 75 RPM).
- Disclosed is a process for preparing a Multi-Unit Pellet System (MUPS) which is a compressed tablet by providing pellets comprising a core, comprising a biologically active ingredient, and a coating layer, comprising a mixture of a first polymer, with is a core-shell polymer, comprising 50 to 90, preferably 70 to 80% by weight of a core, comprising polymerized units of 60 to 80, preferably 65 to 75% by weight of ethyl acrylate and 20 to 40, preferably 25 to 35% by weight of methyl methacrylate, and 10 to 50, preferably 20 to 30% by weight of a shell, comprising polymerized units of 40 to 60, preferably 45 to 55% by weight of ethyl acrylate and 40 to 60, preferably 45 to 55 by weight of methacrylic acid, and a second polymer, polymerized from 40 to 60% by weight of methacrylic acid and 40 to 60% by weight of ethyl acrylate or methyl methacrylate, wherein the ratio of the first polymer to the second polymer is from about 1:0.1 to 1:10, preferably from 1:0.1 to 1:2.5, adding matrix excipients and compression of the mixture to a compressed tablet.
- Disclosed is a Multi-Unit Pellet System (MUPS) as described herein, comprising a biologically active ingredient, preferably a compressed tablet, for use as a medicament in the therapy and treatment of a disease of the human or animal body, wherein the disease is selected from ulcers of the stomach and duodenum, NSAID-induced ulcers, Helicobacter pylori infections, gastrointestinal reflux disease or Zollinger-Ellison syndrome, arthrosis, pain and inflammation and wherein the biologically active ingredient is selected from esomeprazole, dexlansoprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole or any combinations thereof and from a combination of esomeprazole and naproxen.
- Disclosed is a Multi-Unit Pellet System (MUPS) as described herein, comprising a biologically active ingredient, preferably a compressed tablet, for use (method of treatment) as a medicament in the therapy and treatment of a disease of the human or animal body, wherein the disease is selected from ulcers of the stomach and duodenum, NSAID-induced ulcers, Helicobacter pylori infections, gastrointestinal reflux disease or Zollinger-Ellison syndrome, arthrosis, pain and inflammation and wherein the biologically active ingredient is selected from a combination of a proton pump inhibitor with a nonsteroidal anti-inflammatory drug (NSAID), preferably a combination of esomeprazole and naproxen.
-
TABLE 1 Formula (C1-C6) Formula for coating of pellets Experiments on combination of EUDRAGIT ® FL with EUDRAGIT® L for MUPS formulations containing low solubility actives Experiment number C1 C2 C3 C4 C5 C6 Ingredients % w/w composition Lansoprazole 8.87 7.04 7.84 7.03 7.84 6.81 Substrate pellets 62.11 49.26 54.89 49.19 54.87 47.69 HPMC (3 cps) 10.65 8.44 9.41 8.43 9.41 8.18 TiO2 2.13 1.69 1.88 1.69 1.88 1.64 Eudragit ® NM 30 D — — 7.68 10.33 4.61 8.01 Eudragit ® L 30 D-55 — — 7.68 10.33 10.75 14.02 Eudragit ® FL 30 D-55 8.70 20.69 — — — — Sodium hydroxide — — 0.10 0.14 0.14 0.19 Talc 7.54 12.88 10.50 12.86 10.50 13.47 Total 100.00 100.00 100.00 100.00 100.00 100.00 Abbreviations: HPMC: Hydroxy propyl cellulose, cps: centipoise, TiO2: Titanium dioxide, MCC: Microcrystalline cellulose -
TABLE 2 Formula for MUPS (C1-C6) Ingredients % Coated pellets 42.81 MCC 101 granules (#20 passed) 10.81 MCC 102 3 MCC 200 29.53 Ceolus KG 802 10.31 Ac Di sol SD 711 2.26 Aerosil 200 0.71 Sodium Stearyl fumarate 0.57 Total 100.00 -
-
- I. To a part of water, talc was added and homogenized for 15-20 min.
- II. Remaining part of water was used to rinse the homogenizer and added to Step I.
- III. Dispersion of Step II added to EUDRAGIT® FL 30 D-55 under stirring.
- IV. Stirring was continued till 10 min.
- V. The coating dispersion was passed through 40 # ASTM sieve (425 μm)
-
-
- I. To a part of water talc was homogenized for about for 15-20 min.
- II. Remaining part of water was used to rinse the homogenizer and added to Step I.
- III. Dispersion of Step II was added to EUDRAGIT® NM 30 D under stirring.
- IV. EUDRAGIT® L 30 D-55 was neutralized (by 6%) using 1N NaOH. The pH was brought to around 5.
- V. The dispersion of Step IV was added to Step III, slowly under stirring.
- VI. The final coating solution was passed through 40 # ASTM sieve (425 μm)
- The commercially procured Lansoprazole pellets (18#-20#) were barrier coated with HPMC and then was coated with functional coat (Please refer the Formula section)
- The general process parameters are enlisted below:
-
TABLE 3 Process details (4) Experiment number C1*-C2 C3-C6 Parameters Unit Value Value Equipment setup Nozzle bore mm 0.8 0.8 Internal silicone tube mm 2 2.5 diameter Process parameter setup Atomizing air pressure bar 1.0 1.0 Filter shaking Interval sec Manual 180 Filter shaking sec 05 Air flow m3/h 12.0-18.0 30-60 Process data Inlet Temperature ° C. 31-35 32-35 Product Temperature ° C. 26-30 27-36 Spray rate g/min — 2-6 *: Batch was executed in Huttlin Microlab (small batch size) -
-
- I. The coated pellets were mixed with tableting excipients.
- II. The compression was carried out using D tooling fitted on a rotary compression machine.
(5) Process for Tablets/MUPS compression - III. The coated pellets were mixed with tableting excipients.
- IV. The compression was carried out using D tooling fitted on a rotary compression machine.
-
TABLE 4 Set tablet compression parameters Experiment number C1 C2 C3 C4 C5 C6 Punch size 10.00 11.00 11.00 11.00 11.00 11.00 (mm) Set Weight 395 498 448 500 448 498 (mg) Observed 110-130 110-130 100-110 100 -100 100-110 100-110 Hardness (N) -
TABLE 5 Comparative examples C1 to C4 Performance of EUDRAGIT ® FL 30 D-55 and physical mixtures of EUDRAGIT ® L 30 D-55 with EUDRAGIT ® NM 30 D (50:50) Examples C1 C2 C3 C4 Lansoprazole pellets barrier coated with HPMC and further with a Lansoprazole barrier functional coating layer of polymeric coated pellets. mixture of EUDRAGIT ® NM 30D and Functional coating with EUDRAGIT ® L30 D-55. Pellets further EUDRAGIT ® FL 30 D-55 compressed into tablets along with excipients Formulation details Pellets Tablets Pellets Tablets Pellets Tablets Pellets Tablets Ratio of NM:L in coating 75:25 — 75:25 — 50:50 — 50:50 — Process without additional Yes — Yes — No — No — neutralization step Polymeric coat build up (% 10 — 30 — 20 — 30 — w/w) w.r.t core Enteric protection (<10% Yes Yes Yes Yes Yes Yes Yes Yes release in 0.1N HCl, 1 hr) % Drug release within 2 hrs No No No No Yes Yes Yes Yes of pH 6.8 buffer exposure more than 50% Drug release in 1 hr** 0.44** 3.10** 1.30** 3.32** 0.00** 2.97** 3.78** 2.98** 0.1N HCl 0.5 hr 30.00 27.18 21.83 10.35 84.29 66.85 46.98 46.17 followed by pH 1 hr 34.80 32.53 24.60 14.44 103.00 89.33 101.00 80.67 6.8 1.5 hr 38.26 39.57 — — 104.00 93.46 103.00 84.79 2 hr — — — — — — — — F2 value* comparing 81 52 45 43 dissolution profiles of pellets and compressed tablets (≥50% denotes similarity) Comments Not acceptable. Not acceptable. Not acceptable. Not acceptable. Slow release Slow release Pellets and Pellets and from pellets from pellets tablet profiles tablet profiles and tablets and tablets significantly significantly dissimilar, dissimilar, Additional Additional neutralization neutralization step needed. step needed. *No F2 verification needed if the release in tablets is faster than pellets in buffer phase **Release in 0.1N HCl -
TABLE 6 Comparative examples C5 and C6: Performance of physical mixture of EUDRAGIT ® L 30 D-55 with EUDRAGIT ® NM 30 D (30:70) C5 C6 Lansoprazole pellets barrier coated with HPMC and further with a functional coating layer of polymeric mixture of EUDRAGIT ® NM 30D and EUDRAGIT ® L 30 D-55. Pellets further Examples compressed into tablets along with excipients Formulation details Pellets Tablets Pellets Tablets Ratio of NM:L in coating 30:70 — 30:70 — Process without additional neutralization No — No — step Polymeric coat build up (% w/w) w.r.t 20 — 30 — core Enteric protection (<10% release in 0.1N Yes No Yes Yes HCl, 1 hr) % Drug release within 2 hrs of pH 6.8 Yes Yes Yes Yes buffer exposure more than 50% Drug release 1 hr** 0.05** 9.74** 0.35** 8.73** in 0.1 N HCl 0.5 hr 77.32 54.10 26.68 26.34 followed by 1 hr 100.00 70.80 92.93 61.65 pH 6.8 1.5 hr 103.00 77.74 99.99 70.81 2 hr — — — — F2 value* comparing dissolution profiles 32 33 of pellets and compressed tablets (≥50% denotes similarity) Comments Not acceptable. Pellets and tablet dissolution Not acceptable. Pellets and tablet profiles significantly dissimilar, dissolution profiles significantly Additional neutralization step needed. dissimilar. Additional neutralization step needed. *No F2 verification needed if the release in tablets is faster than pellets in buffer phase; **Release in 0.1 N HCl. -
TABLE 7 Formula for coating of pellets Experiment number I1 I2 I3 I4 I5 I6 I7 I8 I9 Ingredients % w/w composition Lansoprazole 8.33 7.63 7.04 7.42 7.04 6.56 6.56 4.80 5.43 Substrate pellets 58.31 53.40 49.26 51.95 49.26 45.93 45.93 33.61 37.98 HPMC (3 cps) 10.00 9.16 8.44 8.91 8.44 7.87 7.87 5.76 6.51 Eudragit FL ® 30 D-55 8.16 11.21 13.79 7.27 8.28 9.52 6.35 9.41 3.26 Eudragit L ® 30 D-55 4.08 5.61 6.90 10.91 12.41 14.28 17.45 25.88 27.76 Talc 11.12 12.99 14.56 13.54 14.56 15.84 15.84 20.53 15.61 Total 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 Abbreviations: HPMC: Hydroxy propyl cellulose, cps: centipoise, MCC: Microcrystalline cellulose -
TABLE 8 Formula for MUPS (I1-I9) Ingredients % Coated pellets 42.81 MCC 101 granules (#20 passed) 10.81 MCC 102 3 MCC 200 29.53 Ceolus KG 802 10.31 Ac Di sol SD 711 2.26 Aerosil 200 0.71 Sodium Stearyl fumarate 0.57 Total 100.00 -
-
- I. To a part of water talc was homogenized for about for 15-20 min.
- II. Remaining part of water was used to rinse the homogenizer and added to Step I.
- III. Dispersion of EUDRAGIT® FL 30 D-55 was added to EUDRAGIT® L 30 D-55, slowly under stirring.
- IV. The dispersion of Step III was added to Step IV, under stirring.
- V. The final coating solution was passed through 40# ASTM sieve (425 μm)
- The commercially procured Lansoprazole pellets (18#-20#) were barrier coated with HPMC and then was coated with functional coat (Please refer the Formula section above)
-
TABLE 9 The general process parameters are enlisted below General Process Parameters in GPCG 1.1, bottom spray Parameters Unit Value Equipment setup Nozzle bore mm 0.8 Internal silicone tube diameter mm 3 Column Height mm 16 Process parameter setup Atomizing air pressure bar 1.0 Filter shaking Interval sec 30 Filter shaking sec 10 Air flow m3/h 60-80 Process data Inlet Temperature ° C. 26-36 Product Temperature ° C. 26-27 Spray rate (g/min) 2-8 -
-
- I. The coated pellets were mixed with tableting excipients.
- II. The compression was carried out using D tooling fitted on a rotary compression machine.
-
-
TABLE 10 Experiment number I1 I2 I3 I4 I5 I6 I7 I8 I9 Punch size 11.00 11.00 11.00 11.0 11.00 11.0 11.0 12.5 11.00 (mm) Set Weight 410 456 495 444 469 504 554 784 565.00 (mg) Observed 110-120 110-120 110-120 110-120 110-120 110-120 120-130 120-130 120-130 Hardness (N) -
TABLE 11 Inventive examples I1 to I4: Performance of physical mixture of EUDRAGIT ® L 30 D-55 with EUDRAGIT ® FL 30 D-55 Experiment number I1 I2 I3 I4 I5 I6 Lansoprazole pellets barrier coated with HPMC and further with a functional coating layer of polymeric mixture of EUDRAGIT® FL 30D-55 and EUDRAGIT ® L 30 D-55. Pellets further compressed into tablets along with excipients Formulation details Pellets Tablets Pellets Tablets Pellets Tablets Pellets Tablets Pellets Tablets Pellets | Tablets Ratio of FL: L polymers 1:0.5 — 1:0.5 1:0.5 1:1.5 1:1.5 1:1.5 used for coating Effective ratio of NM:L 50:50 — 50:50 — 50:50 — 30:70 — 30:70 — 30:70 — Process without Yes — Yes — Yes — Yes — Yes — Yes — additional neutralization step Polymeric coat build up 15 — 22 — 30 — 25 — 30 — 37 — (% w/w) w.r.t core Enteric protection Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes (<10% release in 0.1N HCl, 1 hour) % Drug release in Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Buffer 6.8 in 2 hrs should be more than 50% Drug release 1 hr** 0** 6.13** 0.55** 5.03** 0.52** 3.77** 0.21** 7.38** 0.36** 8.71** 0.11** 5.03** in 0.1 N HCl 0.5 hr 36.99 28.76 34.78 31.50 29.98 24.57 81.70 79.86 70.40 75.89 5.06 14.40 followed by 1 hr 51.30 35.75 44.49 39.00 40.89 33.08 91.10 89.30 99.70 85.29 59.60 68.10 pH 6.8 1.5 hr 59.98 61.83 51.40 49.30 48.93 40.74 — 92.75 102.00 95.10 88.12 89.70 2 hr 68.56 81.12 60.52 55.00 56.07 52.37 — — 104.00 99.45 — — F2 value* comparing 50 67 61 67 53 58 dissolution profiles of pellets and compressed tablets (>50 % denotes similarity) Comments Acceptable Acceptable Acceptable Acceptable Acceptable Acceptable release profiles. release profiles. release profiles. release profiles. release profiles. release profiles. Neutralization Neutralization Neutralization Neutralization Neutralization Neutralization of polymers of polymers of polymers of polymers of polymers of polymers not needed. not needed. not needed. not needed. not needed not needed *No F2 verification needed if the release in tablets is faster than pellets in buffer phase; **Release in 0.1N HCl -
TABLE 12 Inventive examples I7 to I9: Performance of physical mixture of EUDRAGIT ® FL 3C D-55 with EUDRAGIT® L 30 D-55 Example number I7 I8 I9 Lansoprazole pellets barrier coated with HPMC and further with a functional coating layer of polymeric mixture of EUDRAGIT ® FL 30D-55 and EUDRAGIT ® L 30 D-55. Formulation Pellets further compressed into tablets along with excipients details Pellets Tablets Pellets Tablets Pellets Tablets Ratio of FL: L polymers 1:2.75 — 1:2.75 — 1:6.75 — used for coating Effective ratio of NM:L 20:80 — 20:80 — 10:90 — Process without additional Yes — Yes — Yes — neutralization step Polymeric Coat build up 37 — 75 — 50 — (%w/w) w.r.t core Enteric protection (<10% Yes Yes Yes Yes Yes Yes release in 0.1 N HCI, 1 hr) % Drug release in Buffer 6.8 Yes Yes Yes Yes Yes Yes in 2hr should be more than 50% Drug release in 1 hr** 0.00** 5.50** 0.00** 1.76** 0.58** 8.44** 0.1N HCl followed by 0.5 hr 6.12 73.40 1.60 20.00 71.97 81.50 pH 6.8 1 hr 89.70 103.00 14.80 73.80 87.20 94.68 1.5 hr 108.00 107.00 64.50 108.00 96.18 98.03 2 hr 113.00 108.00 107.00 114.00 97.11 102.39 F2 value* comparing Faster drug release in Faster drug release in Faster drug release in dissolution profiles of buffer for tablets buffer for tablets buffer for tablets pellets and compressed compared to coated compared to coated compared to coated tablets pellets. No F2 pellets. No F2 pellets. No F2 (≥50 % denotes similarity) comparison needed comparison needed comparison needed Comments Acceptable release Acceptable release Acceptable release profiles. Neutralization of profiles. Neutralization of profiles. Neutralization of polymers not needed. polymers not needed. polymers not needed. *No F2 verification needed if the release in tablets is faster than pellets in buffer phase; **Release in 0.1N HCl
Claims (19)
1-28. (canceled)
29. A pellet, comprising:
a core, comprising one or more biologically active ingredients, and
a coating layer onto the core,
wherein the coating layer comprises a mixture of a first polymer and a second polymer,
wherein the first polymer is a core-shell polymer, comprising 50 to 90 by weight of a core-shell polymer core, comprising polymerized units of 60 to 80% by weight of ethyl acrylate and 20 to 40% by weight of methyl methacrylate, and
wherein the core-shell polymer comprises 10 to 50% by weight of a core-shell polymer shell, comprising polymerized units of 40 to 60% by weight of ethyl acrylate and 40 to 60% by weight of methacrylic acid, and
wherein the second polymer comprises polymerized units of 40 to 60 by weight of methacrylic acid and 60 to 40% by weight of ethyl acrylate or methyl methacry late, and
wherein a ratio of the first polymer to the second polymer is from about 1:0.1 to 1:10.
30. The pellet according to claim 29 , wherein the core and/or the coating layer comprises a pharmaceutically or nutraceutically acceptable excipient.
31. The pellet according to claim 29 , wherein the coating layer comprises 2% by weight or less of a plasticizer.
32. The pellet according to claim 29 , wherein the one or more biologically active ingredients are selected from the group consisting of an active pharmaceutical ingredient and an active nu raceutical ingredient.
33. The pellet according to claim 29 , wherein the one or more biologically active ingredients are selected from the group consisting of an analgetic, an antibiotic, an anti-infective, an antibody, an antiepileptic, an antigen from plants, an antirheumatic, betablocker, a benzimidazole derivative, a beta-blocker, a cardiovascular drug, a chemotherapeutic, a CNS drug, a digitalis glycoside, a gastrointestinal drug, a combination of proton pump inhibitors with a nonsteroidal anti-inflammatory drug (NSAID), an enzyme, a hormone, a liquid or solid natural extract, an oligonucleotide, a peptide hormone protein, a therapeutical bacteria, a peptide, a protein, a urology drug, a vaccine, and a salt-form thereof.
34. The pellet according to claim 29 , wherein the one or more biologically active ingredients are selected from the group consisting of gastrointestinal drugs.
35. A Multi-Unit Pellet System (MUPS), comprising a multitude of the pellets according to claim 29 .
36. The Multi-Unit Pellet System (MUPS) according to claim 35 , wherein the multitude of pellets is comprised in a capsule, in a sachet, or in a tablet.
37. The Multi-Unit Pellet System (MUPS) according to claim 36 , wherein the tablet is a compressed tablet, comprising the multitude of pellets embedded in matrix excipients.
38. The Multi-Unit Pellet System (MUPS) according to claim 37 , wherein the compressed tablet comprises 30 to 80% by weight of the matrix excipients and 70 to 20% by weight of the pellets.
39. The Multi-Unit Pellet System (MUPS) according to claim 38 , wherein the matrix excipients are selected from the group consisting of antioxidants, brighteners, binding agents, cushioning agents, flavoring agents, flow aids, glidants, penetration-promoting agents, pigments, plasticizers, polymers, pore-forming agents, stabilizers, and a combination thereof.
40. The Multi-Unit Pellet System (MUPS) according to claim 38 , wherein the matrix excipients comprise microcrystalline cellulose, glycerol monostearate, or lactose.
41. The Multi-Unit Pellet System (MUPS) according to claim 38 , wherein a release curve of the one or more biologically active ingredients from the pellets and that of the compressed tablets show an F2-value of 50 or more.
42. A process for preparing Multi-Unit Pellet System (MUPS according to claim 38 , the process comprising:
providing the multitude of pellets,
adding the matrix excipients, to obtain a mixture, and
compressing the mixture to a compressed tablet.
43. A method of therapy and treatment of a disease of a human or animal body with the Multi-Unit Pellet System (MUPS) according to claim 36 , the method comprising:
administering the Multi-Unit Pellet System (MUPS) as a medicament to or animal in need thereof,
wherein the disease is selected from the group consisting of an ulcer of the stomach and duodenum, a NSAID-induced ulcer, a Helicobacter pylori infection, gastrointestinal reflux disease, Zollinger-Ellison syndrome, arthrosis, pain, and inflammation, and
wherein the one or more biologically active ingredients is selected from the group consisting of esomeprazole, dexlansoprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole, a combination thereof, and a combination of esomeprazole and naproxen.
44. The pellet according to claim 33 , wherein the salt-form is an aspartate or a hydrochloride.
45. The pellet according to claim 34 , wherein the one or more biologically active ingredients are selected from the group consisting of proton pump inhibitors.
46. The pellet according to claim 34 , wherein the one or more biologically active ingredients are selected from the group consisting of esomeprazole, dexlansoprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole, a combination thereof, and a combination of esomeprazole and naproxen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/856,817 US20220331254A1 (en) | 2019-04-30 | 2022-07-01 | Pellet and multi-unit pellet system (mups) |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201941017213 | 2019-04-30 | ||
IN201941017213 | 2019-04-30 | ||
PCT/EP2020/058534 WO2020221522A1 (en) | 2019-04-30 | 2020-03-26 | Pellet and multi-unit pellet system (mups) |
US202117606928A | 2021-10-27 | 2021-10-27 | |
US17/856,817 US20220331254A1 (en) | 2019-04-30 | 2022-07-01 | Pellet and multi-unit pellet system (mups) |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/606,928 Continuation US11406599B2 (en) | 2019-04-30 | 2020-03-26 | Pellet and multi-unit pellet system (MUPS) |
PCT/EP2020/058534 Continuation WO2020221522A1 (en) | 2019-04-30 | 2020-03-26 | Pellet and multi-unit pellet system (mups) |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220331254A1 true US20220331254A1 (en) | 2022-10-20 |
Family
ID=70224322
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/606,928 Active US11406599B2 (en) | 2019-04-30 | 2020-03-26 | Pellet and multi-unit pellet system (MUPS) |
US17/856,817 Abandoned US20220331254A1 (en) | 2019-04-30 | 2022-07-01 | Pellet and multi-unit pellet system (mups) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/606,928 Active US11406599B2 (en) | 2019-04-30 | 2020-03-26 | Pellet and multi-unit pellet system (MUPS) |
Country Status (6)
Country | Link |
---|---|
US (2) | US11406599B2 (en) |
EP (1) | EP3962465A1 (en) |
JP (1) | JP2022533028A (en) |
CN (1) | CN113747887A (en) |
CA (1) | CA3134989A1 (en) |
WO (1) | WO2020221522A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110150945A1 (en) * | 2008-08-11 | 2011-06-23 | Mepha Gmbh | Oral pharmaceutical formulation for omeprazole comprising a specific separation layer |
MX353427B (en) | 2011-06-17 | 2018-01-12 | Evonik Roehm Gmbh | Coating composition suitable for pharmaceutical or nutraceutical dosage forms. |
AU2011370763A1 (en) | 2011-06-17 | 2013-10-03 | Evonik Rohm Gmbh | Coating composition suitable for pharmaceutical or nutraceutical dosage forms |
SI2887925T1 (en) * | 2012-08-27 | 2017-06-30 | Evonik Roehm Gmbh | Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol |
BR112015018895A2 (en) * | 2013-02-13 | 2017-07-18 | Evonik Roehm Gmbh | multiparticulate pharmaceutical composition comprising a multiplicity of two types of pellets |
CN104758937B (en) * | 2014-01-02 | 2019-05-21 | 石药集团中奇制药技术(石家庄)有限公司 | A kind of metoprolol sustained-release pellet preparations |
-
2020
- 2020-03-26 EP EP20717562.1A patent/EP3962465A1/en not_active Withdrawn
- 2020-03-26 CA CA3134989A patent/CA3134989A1/en active Pending
- 2020-03-26 US US17/606,928 patent/US11406599B2/en active Active
- 2020-03-26 WO PCT/EP2020/058534 patent/WO2020221522A1/en unknown
- 2020-03-26 JP JP2021564615A patent/JP2022533028A/en not_active Withdrawn
- 2020-03-26 CN CN202080032001.8A patent/CN113747887A/en active Pending
-
2022
- 2022-07-01 US US17/856,817 patent/US20220331254A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20220142928A1 (en) | 2022-05-12 |
JP2022533028A (en) | 2022-07-21 |
CN113747887A (en) | 2021-12-03 |
EP3962465A1 (en) | 2022-03-09 |
WO2020221522A1 (en) | 2020-11-05 |
US11406599B2 (en) | 2022-08-09 |
CA3134989A1 (en) | 2020-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101855805B1 (en) | Alcohol resistant enteric pharmaceutical compositions | |
JP2002500665A (en) | Omeprazole preparation | |
SG190905A1 (en) | Orally disintegrating tablet | |
US20080095853A1 (en) | Modified Release For Proton Pump Inhibitors | |
US9895318B2 (en) | Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanol | |
US11291660B2 (en) | Method of treating heart failure with preserved ejection fraction by administering milrinone | |
US20230048354A1 (en) | Dosage form for use in treating or preventing of a disease | |
US20230000780A1 (en) | Dosage form comprising an alkaline agent and an enteric coating layer | |
CN109152772B (en) | Oral pharmaceutical composition of nicotinamide | |
WO2017017679A1 (en) | Compositions comprising atorvastatin or a pharmaceutically acceptable salt thereof | |
US11406599B2 (en) | Pellet and multi-unit pellet system (MUPS) | |
EP2535045A1 (en) | Pharmaceutical composition of lansoprazole | |
EP4072532B1 (en) | Dosage form for use in treating or preventing of a disease | |
EP3251661A1 (en) | Raloxifene sprinkle composition | |
EP4176874A1 (en) | Pharmaceutical or nutraceutical composition with an alcohol resistant single layer coating system | |
WO2024120944A1 (en) | Delayed release composition with resistance against fed state gastric conditions | |
NZ732954B2 (en) | Method of Treating Heart Failure with Preserved Ejection Fraction with 5-(Pyridinyl)-2(1H)-pyridinone Compounds | |
Kumar | Formulation and Evaluation of Delayed Release Tablet Dosage form Containing a Model Proton Pump Inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |